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Background: Glaucoma is a disease that is associated with elevated intraocular pressure. 
Most commonly, single active agent beta-adrenoceptor blockers (particularly, timolol-only 
preparations) are used as a first-line therapy for primary open-angle glaucoma (POAG).
Purpose: To compare the efficacy of various timolol-only preparations available in the 
Ukrainian pharmaceutical market as a monotherapy for POAG on the basis of expert 
assessment.
Methods: Forty-four ophthalmologists from various Ukrainian regions participated in the 
questionnaire survey. The participants varied in length of service, academic degree and 
experience in managing the disease. Survey data were processed using the method of the 
prior ranking of factors.
Results: Mathematic modeling was used to construct the bar chart of ranks from the 
processed results of the survey. The overall impact of any factor on the examined variable 
was assessed through the sum of ranks.
Conclusion: The method of the prior ranking of factors was used to establish that, in 
the opinion of the surveyed ophthalmologists, CUSIMOLOL, ARUTIMOL and OFTAN 
TIMOLOL are the three most efficient timolol-only preparations for the treatment of POAG.
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Introduction
Glaucoma is a disease that is associated with elevated 
intraocular pressure (IOP) and results in optic nerve damage 
with progression to optic nerve atrophy which can lead to 
loss of visual functions and even blindness. Early disease 
is characterized by an absence of patient’s complaints, but 
as the disease progresses to more severe stages, the visual 
fields gradually constrict, and optic nerve atrophy becomes 
irreversible. In addition, the patient partially loses visual 
functions, which may limit his/her physical activity and 
affect his/her professional performance. Primary open-
angle glaucoma (POAG) is the most common clinical form 
of the disease; it accounts for 70% to 92% of cases [1, 2].
  The age at diagnosis of POAG has decreased with 
time [1]. This is an important social issue since an increase 
in disability rate for individuals of working age will result 
in negative economic consequences for the nation.
Adequate choice of anti-glaucoma drugs and planning 
for use of funds for these agents are essential.
Beta-adrenoceptor blockers and synthetic prostaglandin 
analogues are used as a first-line therapy to improve 
aqueous humor outflow, and are followed by adjunctive 
alpha adrenomimetics and cholinergic drugs if necessary. 
Most commonly, single active agent preparations, 
particularly, timolol-only preparations, are used as a first-
line therapy for POAG.
The purpose of this study was to compare the efficacy 
of various timolol preparations available in the Ukrainian 
pharmaceutical market as a monotherapy for POAG on the 
basis of expert assessment.
Material and Methods
We examined the national medication register and 
identified timolol-only preparations used in POAG therapy. 
In addition, we conducted a questionnaire survey to 
identify a relative efficacy of timolol-only preparations in 
the treatment of POAG on the basis of expert assessment.
Survey data were processed using the method of the 
prior ranking of factors [3,4].
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Results and Discussion
Forty-four ophthalmologists from various Ukrainian 
regions participated in the survey. The participants varied 
in length of service, academic degree and experience in 
managing the disease. They were proposed to determine 
the trademarks under which they most commonly 
clinically administer timolol as a monotherapy and which 
are most effective for POAG, on the basis of their personal 
theoretical knowledge and practical experience.
The main efficacy criteria were a decrease in IOP, 
minimal daily IOP fluctuations, duration of hypotensive 
action, safety and easy administration. It is these 
characteristics that were taken into account by the 
ophthalmologists involved in assessment.
We examined the national medication register and 
identified 10 timolol-only preparations registered in 
Ukraine as of January 20, 2019 [5].  For convenience of 
data processing, the identified preparations were assigned 
corresponding designations:
ARUTIMOL® 5 mg/ml eye drop solution supplied in 
a 5-ml dropper bottle enclosed in a carton (Dr. GERHARD 
MANN Chem.-Pharm. Fabrik, GmbH, Germany, and 
Laboratoire CHAUVIN, France), factor X1;
CUSIMOLOL® 0.5% eye drop solution supplied in a 
5-ml dropper bottle enclosed in a carton (Alcon Cusi SA, 
Spain), factor X2;
NORMATIN 0.5% eye drop solution supplied in a 
5-ml dropper bottle enclosed in a carton (EIPI Co., Egypt), 
factor X3;
OCUMED 0.5% eye drop solution supplied in a 5-ml or 
10-ml plastic dropper bottle enclosed in a pack (PROMED 
EXPORTS Pvt Ltd, India), factor X4;
OFTAN® TIMOLOL 0.5% eye drops supplied in 
a 5-ml dropper bottle enclosed in a carton (Santen AT, 
Finland), factor X5;
OFTIMOL® 0.5% 5 mg/ml eye drop solution supplied 
in a 5-ml or 10-ml plastic bottle enclosed in a carton 
(FARMAK JSC, Ukraine), factor X6;
TIMOLOL 0.5% eye drop solution supplied in a 5-ml 
bottle with a dropper cap enclosed in a pack (Elegant 
India, India), factor X7;
TIMOLOL-DARNYTSIA 5 mg/ml eye drop solution 
supplied in a 5-ml or 10-ml bottle enclosed in a pack 
(Darnytsia Pharmaceutical Company JSC, Ukraine), 
factor X8;
TIMOLOL MALEAT 5 mg/ml eye drop solution 
supplied in a 5-ml or 10-ml bottle enclosed in a pack 
(FARMAK JSC, Ukraine), factor X9; and
TIMOLOL MALEAT 5 mg/ml eye drop solution 
supplied in a 5-ml or 10-ml glass bottle with a dropper cap 
enclosed in a pack (BIOFARMA, Kyiv, Ukraine), factor 
X10.
The participants were asked to arrange the preparations 
in descending order of efficacy on the basis of personal 
clinical experience, and to assign them ranks from 1 (best 
characteristics) to 10 (worst characteristics). Results of the 
survey are summarized in Table 1.
Since some participants failed to distinguish the effect 
of factors on the studied characteristic and assigned equal 
ranks to some factors, we had to transform the ranks.
For this purpose, we used the following formula:
where a is the transformed rank; k1 is a number of equal 
ranks in the corresponding rank group for the participant; 
and k2 is a number of factors preceding a group of factors 
with equal ranks.
We created a matrix of transformed ranks on the basis 
of (a) results of expert assessment of timolol preparation 
efficacy, (b) primary processing of these results and (c) 
rank transformation (Table 2).
The survey results were processed in the following way. 
First, the sum of ranks for each factor was determined:
where m is the number of survey participants.
Second, the deviation from the mean rank sum was 
calculated:
where Sj is the deviation of rank sum of factor j from 
the mean rank sum; k is the number of factors, 
and1/k is the mean rank sum.
Kendall’s coefficient of concordance was used to assess 
the level of agreement between experts:
where u is the number of groups formed by factors 
having equal ranks in i-ranking; tu is the number of equal 
ranks in u-group of i-ranking; 
is the sum of squares for  the deviation 
of rank sum of factor j from the mean rank sum; k is the 
number of factors, and m k is the number of experts.
In our case, the coefficient of concordance was 0.3. A 
low value of the coefficient likely can be explained by that 
experts experienced difficulties in ranking due to a large 
number of factors.
The chi-square test was used to assess the statistical 
significance of the coefficient of concordance. For a sample 
size of 10, or 10-1=9 degrees of freedom, we obtained a 
tabulated chi-square statistic of 16.9 at а=0.05. Because 
the calculated chi-square statistic (χ2calc=107.57) was 
greater than the tabulated chi-square value at the 0.05 level 
of significance, expert opinions agreed with each other.
With regard to expert assessment of timolol-only 
preparations used in POAG therapy, mathematic modeling 
was used to construct the bar chart of ranks from the 
processed results of the survey (Fig. 1).
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The overall impact of any factor on the examined 
variable was assessed through the sum of ranks: the less 
the sum of ranks, the greater the impact of the examined 
factor.
Therefore, in the opinion of experts, the following 
preparations were the best with regard to efficacy of 
treatment: CUSIMOLOL® 0.5% eye drop solution 
supplied in a 5-ml dropper bottle enclosed in a carton 
(Alcon Cusi SA, Spain); ARUTIMOL® 5 mg/ml eye drop 
solution supplied in a 5-ml dropper bottle enclosed in a 
carton (Dr. GERHARD MANN Chem.-Pharm. Fabrik, 
GmbH, Germany, and Laboratoire CHAUVIN, France); 
OFTAN® TIMOLOL 0.5% eye drops supplied in a 5-ml 
dropper bottle enclosed in a carton (Santen AT, Finland).
Conclusion
First, we examined the national medication register 
and identified 10 timolol-only preparations registered 
under various trade names for the treatment of glaucoma 
in Ukraine.
Second, the method of the prior ranking of factors 
was used to establish that, in the opinion of the surveyed 
ophthalmologists, CUSIMOLOL, ARUTIMOL and 
OFTAN TIMOLOL are the three most efficient timolol-
only preparations for the treatment of POAG.
References 
1. Kryvov’iaz OV. [Glaucoma patients’ quality of life: social 
and pharmacoeconomic aspects]. Dnipro: Litograf; 2017. 
Ukrainian.
2. European Glaucoma Society. Terminology and guidelines for 
glaucoma. 4th ed. Savona: PubliComm; 2014. 
3. Groshovyi TA, Martseniuk VP, Kucherenko LІ, et al. 
[Mathematic planning of experiments in pharmaceutical 
research]. Ternopіl: Ukrmedkniga; 2008. Ukrainian.
4. Babintseva LIu. [Expert survey to assess the efficacy 
of medications]. Medychna informatika ta inzheneriia. 
2014;1:21-3. Ukrainian.
5. The State Register of Medicinal Products of Ukraine. 
Available from: http://www.drlz.com.ua. Ukrainian.
    The authors certify that they have no conflicts of 
interest in the subject matter or materials discussed in 
this manuscript.
ISSN 0030-0675. Journal of Ophthalmology (Ukraine) - 2020 - Number 4 (495) 
86   
Table 1. Results of the survey of ophthalmologists on the impact of factors on the efficacy of timolol preparations
Number assigned 
to an ophthalmologist 
Factor number 
X1 X2 X3 X4 X5 X6 X7 X8 X9 X10
1 1 3 10 9 2 4 8 7 5 6
2 2 3 8 9 1 10 7 6 4 5
3 2 1 3 6 4 5 7 8 9 10
4 5 2 6 7 1 8 9 10 3 4
5 2 1 5 9 3 4 8 7 6 10
6 4 3 5 6 2 1 10 9 8 7
7 1 2 3 6 5 4 7 8 10 9
8 6 2 7 5 1 8 10 9 3 4
9 4 3 4 2 3 1 4 4 5 6
10 2 1 8 5 4 3 6 9 10 7
11 2 1 5 10 8 3 4 7 6 9
12 1 3 10 9 2 4 8 7 5 6
13 2 3 8 9 1 10 7 6 4 5
14 3 1 4 3 1 3 2 2 3 3
15 4 1 6 7 2 8 9 10 3 5
16 1 2 5 8 3 4 9 10 6 7
17 5 4 3 6 1 2 10 8 9 7
18 1 2 3 4 5 6 7 9 10 8
19 6 3 7 4 1 8 9 5 2 10
20 3 1 3 2 1 3 2 1 2 4
21 2 4 7 5 1 3 6 9 10 8
22 2 1 5 10 6 3 8 7 4 9
23 2 5 7 1 3 4 10 8 6 9
24 1 2 3 6 4 5 7 8 9 10
25 2 1 6 5 3 4 10 9 7 8
26 3 7 6  4 5 8 2 1  
27 1 3   2      
28 2 1  4 3 5     
29 3 2 5  1   4   
30 2    1  3 4 5 6
31 4    3   3  4
32 1 3     4 5 2  
33 2 3  8 1 7 2 5 6  
34 1 2 3  4  6 5 7 8
35 2 4  8 1 5 9 7 6 3
36 3    2 1 5 6 4 7
37 3 2  4 1 5 7 6 8 9
38 2 3 8 10 1 9 7 6 4 5
39 1 3   3  3 4 7 6
40 3 2 4 6 1 5     
41 6 3 7 4 1 9 8 5 2 10
42 4 3 5 6 2 1 10 9 8 7
43 3 2 8 7 1 5 10 6 4 9
44 1 2 6 3 4 5 7 8 9 10
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Table 2. Matrix of transformed ranks
Number 
assigned 
to an 
ophthal-
mologist
Factor number tu Ti
X1 X2 X3 X4 X5 X6 X7 X8 X9 X10 0 0
1 1 3 10 9 2 4 8 7 5 6 0 0
2 2 3 8 9 1 10 7 6 4 5 0 0
3 2 1 3 6 4 5 7 8 9 10 0 0
4 5 2 6 7 1 8 9 10 3 4 0 0
5 2 1 5 9 3 4 8 7 6 10 0 0
6 4 3 5 6 2 1 10 9 8 7 0 0
7 1 2 3 6 5 4 7 8 10 9 0 0
8 6 2 7 5 1 8 10 9 3 4 0 0
9 6,5 3,5 6,5 2 3,5 1 6,5 6,5 9 10 2,3 2,5
10 2 1 8 5 4 3 6 9 10 7 0 0
11 2 1 5 10 8 3 4 7 6 9 0 0
12 1 3 10 9 2 4 8 7 5 6 0 0
13 2 3 8 9 1 10 7 6 4 5 0 0
14 7 1,5 10 7 1,5 3 3,5 3,5 7 7 2,2,4 6
15 4 1 6 7 2 8 9 10 3 5 0 0
16 1 2 5 8 3 4 9 10 6 7 0 0
17 5 4 3 6 1 2 10 8 9 7 0 0
18 1 2 3 4 5 6 7 9 10 8 0 0
19 6 3 7 4 1 8 9 5 2 10 0 0
20 8 2 8 5 2 8 5 2 5 10 3,3,3 6
21 2 4 7 5 1 3 6 9 10 8 0 0
22 2 1 5 10 6 3 8 7 4 9 0 0
23 2 5 7 1 3 4 10 8 6 9 0 0
24 1 2 3 6 4 5 7 8 9 10 0 0
25 2 1 6 5 3 4 10 9 7 8 0 0
26 3 7 6 4 5 8 2 1 0 0
27 1 3 2 0 0
28 2 1 4 3 5 0 0
29 3 2 5 1 4 0 0
30 2 1 3 4 5 6 0 0
31 4 3 3 4 0 0
32 1 3 4 5 2 0 0
33 2 3 8 1 7 2 5 6 0 0
34 1 2 3 4 6 5 7 8 0 0
35 2 4 8 1 5 9 7 6 3 0 0
36 3 2 1 5 6 4 7 0 0
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Table 2. Matrix of transformed ranks (continuation)
Number 
assigned 
to an 
ophthal-
mologist
Factor number tu Ti
X1 X2 X3 X4 X5 X6 X7 X8 X9 X10 0 0
37 3 2 4 1 5 7 6 8 9 0 0
38 2 3 8 10 1 9 7 6 4 5 0 0
39 1 3 3 3 4 7 6 0 0
40 3 2 4 6 1 5 0 0
41 6 3 7 4 1 9 8 5 2 10 0 0
42 4 3 5 6 2 1 10 9 8 7 0 0
43 3 2 8 7 1 5 10 6 4 9 0 0
44 1 2 6 3 4 5 7 8 9 10 0 0
124,5 102 206,5 220 106 185 280 273 233 274
2,83 2,49 6,07 6,29 2,47 5,00 7,18 6,66 5,97 7,41
Sj -75,9 -98,4 6,1 19,6 -94,4 -15,4 79,6 72,6 32,6 73,6
Sj2 5760,81 9682,56 37,21 384,16 8911,36 237,16 6336,16 5270,76 1062,76 5416,96
 
Fig. 1. Bar chart of ranks given to factors influencing the efficacy of treatment with timolol preparations
